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Abstract
Background: Chronic stress or prolonged administration of glucocorticoids suppresses proliferation and/or survival of
newborn cells in adult rat dentate gyrus. Earlier we showed that administration of the glucocorticoid receptor antagonist
mifepristone during the final 4 days of a 21 days period of corticosterone treatment fully normalized the number of
newborn cells. Here we aimed to better understand how mifepristone achieves this effect and questioned whether an even
shorter (single day) mifepristone treatment (instead of 4 days) also suffices to normalize neurogenesis.
Methods: We investigated various steps of the neurogenic process, using the immunohistochemical markers BrdU,
doublecortin, proliferating cell nuclear antigen as well as glial fibrillary acidic protein, after 17 or 21 days of corticosterone
(versus vehicle) treatment.
Results: Corticosterone primarily attenuates the proliferation of cells which subsequently develop into neurons; this is fully
reversed by mifepristone. Surprisingly, the corticosteroid effects on neurogenesis can even be fully re-set by a single-day
treatment with mifepristone (on day 18), despite the continued corticosterone exposure on subsequent days.
Conclusions: Our results emphasize that studies into the therapeutical efficacy of new antidepressants, especially those
targeting HPA-activity or the glucocorticoid receptor, should explore the possibility to reduce treatment duration.
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Introduction
Exposure to stress leads to activation of hypothalamo-pituitary-
adrenal axis (HPA), eventually resulting in enhanced release of
glucocorticoid hormones from the adrenal. These hormones enter
the brain and bind to intracellular receptors [1]. Glucocorticoid
receptors (GRs) are enriched in limbic areas like the hippocampus
and, due to relatively low affinity for corticosterone, are primarily
activated after stress [2].
Chronic stress and HPA dysfunction are generally considered
risk factors for the development of psychiatric disorders, including
major depression [3,4,5,6]. For instance, HPA-axis hyperactivity is
often seen in depressed patients and even in healthy high-risk
proband with a positive family history for affective disorders
[7,8,9]. HPA dysfunction is partly normalized upon treatment and
the degree of normalization inversely correlates with relapse
probability [10]. Recently, individuals with severe types of
depression, e.g. psychotic depression, were reported to benefit
from treatment with the GR-antagonist mifepristone
[11,12,13,14].
The cellular effects of chronic stress in the brain have been
extensively studied in rodent models, for reviews see [15,16,17,18].
Many parameters in target areas of corticosteroids, e.g. the
hippocampus, are altered after 21 days of stress or treatment with
high doses of corticosterone (the prevailing rat glucocorticoid),
including neurogenesis in the dentate gyrus (DG), for reviews see
[16,19,20,21,22]. Adult neurogenesis refers to the process by
which stem cells located in the subgranular zone undergo
sequential stages of proliferation, migration and neuronal differ-
entiation before incorporated into the existing adult hippocampal
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network [23,24,25,26]. Chronic stress and corticosterone treat-
ment were reported to reduce cell proliferation [27,28,29,30],
neuronal differentiation [31] and/or survival of newborn cells [32]
although also exceptions have been reported, for reviews see
[20,33,34]. Interestingly, the stress-reduced neurogenesis could be
completely normalized by mifepristone administration during final
4 days of stress or corticosterone administration (i.e. on days 18–
21), whereas the drug was ineffective in the handled control group
[35,36]. This may bear relevance to the clinical efficacy of
mifepristone.
How mifepristone achieves this normalizing effect is not well
understood. We performed two experiments to obtain more
insight. If corticosterone would only increase vulnerability to cell
death until day 18 while the actual reduction in newborn cell
number would only take place between days 18–21, then
mifepristone treatment starting at day 18 might prevent the latter
from happening (a ‘rescue’ effect). On the other hand, if
corticosterone would systematically reduce survival of newborn
cells throughout the entire application period, the normalizing
effect of mifepristone might take place between days 18–21, e.g. by
promoting additional rounds of cell division. In the first scenario,
the number of surviving newborn cells up to 17 days of
corticosterone administration is expected to be comparable to
that in vehicle-treated controls. In the latter case the number of
surviving newborn cells will be reduced after 17 days of
corticosterone. Corticosterone might also preferentially attenuate
proliferation, which would then be prevented or reversed by
mifepristone. These possibilities were examined in the first
experiment, by systematically studying cell proliferation and
survival after 17 or 21 days of corticosterone/vehicle administra-
tion. In the second experiment we questioned whether mifepris-
tone treatment for 4 consecutive days is necessary, or whether a
single-day treatment is already sufficient to reverse the chronic
corticosterone effect.
Materials and Methods
Animals
All animal procedures presented in this paper were approved by
the animal ethics committee of the University of Amsterdam. We
here report on data obtained in 48 adult male Wistar rats (8 weeks
of age; 180–200 g on arrival). All animals were housed in pairs
under controlled conditions of a 12/12 h light/dark cycle (lights
on 08:00 h) with food and water ad libitum. They were habituated
to the experimental setting for 10 days. Temperature and
humidity were kept at 20–22uC and 50–55% respectively.
Corticosterone and mifepristone treatment
Corticosterone (CORT; Sigma, C-2505; 40 mg/kg) was
dissolved in arachidus oil. CORT or vehicle (VEHC) was
subcutaneously injected daily at 09:00 h for 17 days or 21 days.
Mifepristone (50 mg/kg body weight; Sigma, St Louis, MO, USA)
was dissolved in 15 mL ethanol/1.5 mL coffee cream (Campina,
Woerden, The Netherlands). In experimental groups examined for
21 days, animals were treated either i) only on day 18 or ii) on days
18–21, both at 09:00 h and 16:00 h with mifepristone or its vehicle
(VEHM), administered through an oral syringe directly into
stomach.
Rats were randomly assigned to one of eight experimental
groups (n = 6 animals per group; see Figure 1 for schedule).
Comparable to our earlier study [36], one group received
corticosterone injections for 21 days and another group received
21 days of corresponding vehicle. Both groups were treated with
the vehicle of mifepristone on days 18–21 (21ds CORT+ds18–21
VEHM and 21ds VEHC+ds18–21 VEHM respectively). In view
of the high reproducibility of corticosterone-induced reduction in
neurogenesis [31,32,36], it was considered valid to use these two
groups as a statistical reference for the two experiments, which is
also in accordance with the European animal research ethics law
that aims for reduction in the number of experimental animals as
much as possible.
For experiment #1, the two reference groups were compared
with a 17 days CORT group (17ds CORT) and a 17 days VEHC
group (17ds VEHC). For experiment #2, we added four groups:
rats received mifepristone treatment during the final 4 days of
corticosterone or vehicle (21ds CORT+ds18–21 MIF; 21ds
VEHC+ds18–21 MIF respectively); and rats receiving 21 days
corticosterone or vehicle, in combination with mifepristone
treatment on day 18 only (21ds CORT+d18 MIF and 21ds
VEHC+d18 MIF, respectively). During treatment all experimental
groups were mixed and animals were sacrificed on next day after
the last treatment (i.e. on d18 or d22 for the 17ds and 21 ds
treatment groups, respectively).
Body weight
Body weights were measured regularly, first at the beginning of
experiment to assess the baseline, and subsequently at daily
intervals. Data are expressed in percentage change of body weight
(weight at the day of sacrifice minus the baseline value divided by
baseline value).
Bromodeoxyuridine labeling
To study survival of newborn cells, all animals received 5-
bromo-2-deoxyuridine (BrdU) intraperitoneally (200 mg/kg body
weight, dissolved in 0.9% saline) at noon on the first day of chronic
CORT or vehicle administration (i.e., 3 h following the first
CORT or VEHC injection). The single injection paradigm was
chosen to ensure that the delay between, and the acute effect of,
the first injection (of CORT or VEHC) and BrdU incorporation
was comparable for all animals.
Figure 1. Schematic representation of experimental groups. In
experiment #1, we compared animals treated subcutaneously with
corticosterone (CORT) or vehicle (VEHC) daily for 17 days with animals
treated for 21 days; the latter groups also received the vehicle of
mifepristone (VEHM) on days 18–21. In experiment #2, the 21 ds CORT/
VEHC+ds 18–21 VEHM were used as statistical reference groups in a
comparison with experimental groups receiving mifepristone on d18
only (21ds CORT+ds18 MIF and 21ds VEHC+ds18 MIF) or on 4 days from
18–21 (21ds CORT+ds18–21 MIF and 21ds VEHC+ds18–21 MIF). All
animals were treated with BrdU on day 1 and sacrificed on the morning
after the last treatment.
doi:10.1371/journal.pone.0046224.g001
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Brain tissue processing
At the day of sacrifice, animals were anaesthesized in the
morning with pentobarbital sodium salt (Nembutal, 1 mg/kg
bodyweight; A.U.V. Cuijk, the Netherlands) and perfused
transcardially with saline followed by 4% paraformaldehyde in
0.1 M phosphate buffer (PB, pH 7.4). To prevent pressure
artefacts, brains were additionally post-fixed overnight in the skull
at 4uC, washed and cryoprotected in 30% sucrose in PB. Frozen
sections (40 mm thick) were cut using a sliding microtome and
collected in PB with sodium azide.
Immunohistochemistry
Different stages of neurogenic process were studied as described
previously [37]. Immunohistochemistry for BrdU (monoclonal
mouse anti-BrdU, Roche Diagnostics, the Netherlands; 1:1000)
was used to assess cell survival of proliferating cells marked at the
first day of corticosterone (or vehicle) administration; PCNA
(monoclonal mouse anti-PCNA, DAKO, 1:400) to assess prolif-
eration; and doublecortin (DCX) (polyclonal goat anti-DCX,
SantaCruz; 1:800) to estimate neurogenesis. To analyze changes in
astrocyte numbers in dentate gyrus, immunohistochemistry for
GFAP (polyclonal rabbit anti-GFAP, DAKO; 1:10000) was done
as well. Amplification was performed with biotinylated secondary
antibodies, sheep anti-mouse (1:200; GE Healthcare), donkey anti-
goat (1:500; Jackson ImmunoResearch Labrotories) and goat anti-
rabbit (1:200; Vector Laboratories) immunoglobulins respectively,
followed by incubation in avidin-biotin complex (1:1000; Elite
Vectastain ABC kit, Brunschwig Chemie, Amsterdam) and
biotinylated tyramide (1:500; 0.01% H2O2; kindly provided by
Dr. I. Huitinga, Netherlands Institute for Neuroscience, Amster-
dam) and avidin-biotin-complex. Chromogen development was
performed with diaminobenzidine (DAB; 20 mg/100 mL Tris
buffer, pH 7.55, 0.01% H2O2).
To assess whether DCX+ neurons can re-engage in cell cycle
and undergo again proliferation, additional double immunofluo-
rescence stainings were performed for Ki67 and DCX in a limited
set of tissue sections from 21ds CORT+d18 MIF rats and their
vehicle treated controls. The following antibodies and conditions
were used; DCX (SantaCruz, polyclonal made in goat; 1:150) and
Ki67 (Novocastra, polyclonal made in rabbit; 1:250). Mounted
sections were first heated in 0.01 M citriate buffer (pH 6.0) in a
microwave oven (Bosch) for 5 minutes at 800 W and then
5 minutes at 400 W followed by 5 minutes at 260 W. After a
cool down period outside the oven of approximately 20 minutes,
the sections were washed and incubated in primary antibodies
diluted in 0.25% gelatine and 0.5% Triton-100 at room
temperature for 1 h, and then incubated overnight at 4uC. The
next day, the sections were washed and incubated for 2 h with
donkey-anti-rabbit biotinylated secondary antibody (for Ki67,
Jackson ImmunoResearch Labrotories; 1:200) and donkey-anti-
goat Alexa 488 antibody (for DCX, Molecular Probes, Leiden,
The Netherlands; 1:200) at room temperature before storage
overnight at 4uC. The next day sections were washed and
incubated for 2 h in Alexa 488-labeled streptavidine antibody (for
Ki67, 1:400, Molecular Probes, Leiden, The Netherlands; 1:400,
green). Following a brief rinse, they were embedded in Vectashield
(Vector Laboratories). Fluorescent signal was detected using a
confocal Nikon A1 laser scanning microscope and simultaneously
collected.
Quantification of DCX, GFAP, BrdU and PCNA
Stereological quantification of the number of DCX+ cells and
GFAP+ cells was performed unilaterally by systematic random
sampling in every 10th section using the StereoInvestigator system
(Microbright field, Germany) according to stereological principles
described previously, for details see [38] and without a left/right
preference within or between animals. Because of relatively low
numbers and the occurrence of clusters, BrdU+ and PCNA+ cells
were counted manually by means of modified stereological
procedure in every 10th hippocampal section (Zeiss microscope
2006 magnification) and multiplied by 10 to estimate the total
number in DG.
Statistics
Data are presented as mean 6 SEM. All statistics were
performed with SPSS 16. Data were subjected to an ANOVA,
using p,0.025 as the level of significance, thereby correcting for
the double use of the references groups (21 ds CORT and 21 ds
VEHC). This was followed by a post-hoc Tukey multiple
comparisons of the means.
Results
General expression patterns of BrdU, DCX, PCNA and
GFAP
BrdU was injected on day 1 and evaluated on day 18
(experiment #1) or day 22 (experiment #1 and 2). This gives
insight in the survival of proliferating cells [39]. BrdU+ cells
prevailed in the subgranular zone (SGZ; see Figure 2A for typical
example) but were also found in the hilus and -in considerably
lower numbers- the granule cell layer (GCL).
Doublecortin (DCX) is a microtubule binding protein expressed
in young neurons from approximately 4 to 14 ds after birth of the
cell [40]. DCX+ somata were located mainly in the SGZ and their
processes extended through GCL into the molecular layer (shown
in Figure 2B). In general, ‘gaps’ in the continuous line of DCX
expressing cells in SGZ and shorter extensions were frequently
found in CORT-treated animals compared to controls. We
distinguished morphologically different subtypes of DCX+ neu-
rons, reflecting different stages of neuronal development, as
described before [37]: those without dendrites or with horizontally
orientated dendrites were designated as type 1 cells (shown in
Figure 2C) and cells with dendrites growing into GCL but not the
molecular layer as type 2 cells (Figure 2D); these together are
considered to be less mature neurons which can still undergo cell
division [41]. In contrast, more mature DCX+ neurons are
characterized by a primary dendrite orientated perpendicularly to
the SGZ and with protrusions into the molecular layer (type 3
cells, Figure 2E).
Proliferating cell nuclear antigen (PCNA) is involved in leading
strand synthesis during DNA replication and as such commonly
used as a marker for cell division [42,43]. In accordance with the
literature [44], PCNA+ cells prevailed in SGZ but were also found
in the hilus and to a lesser extent in the outer GCL as clusters, with
multiple cells per cluster (typical examples in Figure 2F).
We further included quantification of the number of GFAP-
positive astrocytes, as these glia cells have been implicated in the
pathogenesis of affective disorders [45] and were found to be
reduced after stress in animal models [46] and in patients suffering
from depression [47,48,49]. Typically, GFAP+ cells showed brown
DAB-staining in the processes and cytoplasm while the nucleus
was devoid of staining and they were present throughout the main
hippocampal subregions (Figure 2G).
Effects of 17 versus 21 days treatment with
corticosterone
Body weight gain was significantly different among the four
experimental groups (ANOVA F(3,20) = 113.8, p,0.001; Table 1).
Stress Hormone Receptor Blockade and Neurogenesis
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Post-hoc analysis revealed that both 17 days and 21 days CORT
exposure significantly (p,0.001) reduced the percentual change in
body weight, compared to the respective vehicle controls. As
expected, the gain in body weight was significantly lower after 17
ds VEHC than after 21 ds VEHC (p,0.05).
The four experimental groups differed significantly from each
other (F(3,20) = 13.7, p,0.001) with respect to the number of
BrdU+ cells (Figure 3A). Post-hoc analysis showed that both 17 ds
(p,0.05) and 21 ds CORT (p,0.001) exposure significantly
reduced the number of BrdU+ cells compared to the respective
controls.
Treatment also significantly affected the total number of DCX+
neurons (F(3,20) = 15.5, p,0.001; Figure 3B1). Both 17 ds CORT
exposure (p,0.001) and 21 ds CORT exposure (p,0.001)
significantly reduced total number of DCX+ neurons compared
to controls at the same day. Treatment effects were reflected
among the immature (type 1+2; ANOVA: F(3,20) = 8.2, p,0.001;
Figure 3B2) as well as more mature (type 3; F(3,20) = 13.6,
p,0.001; Figure 3B3) DCX+ cells. For both immature and mature
DCX+ cells, the reduction in cell number was significant after 17
ds CORT (p,0.05 and p,0.005 respectively) and after 21 ds
CORT exposure (immature neurons and mature neurons: p,0.05
and p,0.001) compared to the respective control groups.
The number of PCNA+ was also significantly (F(3,20) = 13.0,
p,0.001) affected by treatment (Figure 3C). The 17 ds and 21 ds
CORT groups were highly comparable and both showed a
significant (p,0.001 and p,0.005 respectively) reduction in the
number of PCNA+ cells compared to the corresponding control
groups. As shown in Figure 3D, CORT treatment did not affect
the number of GFAP+ astrocytes at all (F(3,20) = 0.977, p.0.05).
For all parameters tested (BrdU, DCX, PCNA, GFAP), the two
VEHC groups (17ds VEHC and 21ds VEHC+d18–21 VEHM)
were highly comparable. Similarly, the 17ds CORT and 21ds
CORT (+d18–21 VEHM) groups did not differ significantly from
each other for any of the markers investigated.
Collectively, these results are not compatible with the idea that
reduction in adult-born cell number starts only .17 ds after the
onset of CORT exposure, so that mifepristone at that time would
exert a ‘rescue’ effect. Rather, our data indicate that throughout its
presence, corticosterone steadily attenuates adult neurogenesis (see
further Discussion).
Effects of mifepristone administered on d18 or ds18–21
of a 3-weeks corticosterone treatment period
We next examined if we could replicate the earlier findings with
mifepristone [36]; and if so, whether the chosen 4-days treatment
period is required for complete reversal, or whether a single-day
treatment at d18 can already ‘reset’ the corticosterone-induced
attenuation of proliferation. To this end, we compared six
experimental groups, which differed from each other with respect
to corticosterone treatment (CORT vs VEHC for 21 ds) and
mifepristone treatment (a single administration of mifepristone on
d18; mifepristone on 4 consecutive days, i.e. ds 18–21; no
Figure 2. Distribution of BrdU, DCX, PCNA and GFAP positive cells in the rat dentate gyrus. A. BrdU+ cells are mainly located in the
subgranular zone (SGZ, arrowhead) but can also be found in the hilus. Considerably lower numbers are encountered in the granular cell layer (GCL).
Calibration bar: 50 mm. B. Overview of the rat dentate gyrus with vehicle treatment showing strong immunoreactivity of DCX in the SGZ and GCL,
with dendrites extending through the GCL into the molecular layer (ML). Calibration bar: 100 mm. C. Arrowhead points to a relatively immature type 1
DCX+ cell, without dendrites and/or with horizontally oriented dendrites. Calibration bar: 10 mm. D. Arrowhead points to a type 2 DCX+ cell, with
dendrites with an oblique orientation, growing into the GCL but not ML. Calibration bar: 10 mm. E. Arrow points to a relatively mature type 3 DCX+
cell, characterized by a primary dendrite orientated perpendicularly to the SGZ and with protrusions extending into the ML. Calibration bar: 10 mm. F.
Clustered PCNA-labeled cells prevail in the SGZ (arrowhead) but can also be found in the hilar region; these cells are less prevalent within the GCL.
Calibration bar: 50 mm. G. GFAP+ astrocytes are mainly located in the hilus and ML but not in the GCL. These cells show brown DAB-staining in their
processes and cytoplasm whereas the nucleus is devoid of staining (arrow). Calibration bar: 10 mm. H. Double immunofluorescent staining
(orthogonal planes) of a DCX-Ki67 double immunopositive cell in the SGZ of a 21ds CORT+d18 MIF treated animal, demonstrating that at least a
subset of the DCX+ cells can re-engage in cell cycle. Arrow indicates red Ki-67 signal in the nucleus of a green DCX+ cell. 406magnification; GCL:
granule cell layer of the hippocampal dentate gyrus.
doi:10.1371/journal.pone.0046224.g002
Table 1. Percentual change in body weight.
Group names VEHC CORT
Experiment 1
21 ds+ds 18–21 VEHM 36.062.0 24.563.0a
17 ds 27.560.9b 20.160.6a
Experiment 2
21 ds+ds 18–21 VEHM 36.062.0 24.563.0a
21ds+d18 MIF 31.460.9 4.260.8a,d
21ds+ds 18–21 MIF 43.161.0c 20.662.1a
Corticosterone (CORT) compared to vehicle treatment (VEHC) reduced the
percentual change in body weight, at 17 and 21 ds. This was not consistently
affected by treatment with mifepristone (MIF).
a: significantly different from the corresponding VEHC group (p,0.001).
b: significantly different from the 21 ds VEHC+ds 18–21 VEHM group (p,0.05).
c: significantly different from the 21 ds VEHC+d18 MIF group (p,0.001).
d: significantly different from the 21 ds CORT group (p,0.05).
doi:10.1371/journal.pone.0046224.t001
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mifepristone, i.e. VEHM on ds 18–21). An overall ANOVA
revealed a significant effect on the percent change of body weight
(F(5,30) = 132.7, p,0.001; Table 1), which was mostly explained
by a significantly reduced body weight in all 21 ds CORT groups,
with or without mifepristone (p,0.001 in all cases). In the VEHC
groups, 4 days of mifepristone administration resulted in more
gain in body weight than in the group which received no
mifepristone at all. Moreover, the 21ds CORT+d18 MIF group
had less attenuated body weight gain than the CORT treated
group receiving no mifepristone.
The number of BrdU+ cells differed among the groups
(F(5,30) = 7.3, p,0.001). We completely reproduced our earlier
finding [36] that mifepristone treatment during ds 18–21 fully
normalizes the CORT-induced reduction in number of BrdU+
Figure 3. Effects of 17 versus 21 days treatment with corticosterone. A. Both 17 ds (p,0.05) and 21 ds CORT (p,0.001) exposure
significantly reduced the number of BrdU+ cells compared to the respective vehicle control groups. B1. Likewise, both 17 ds and 21 ds CORT
exposure significantly (p,0.001) reduced the total number of DCX+ cells compared to the control groups. B2. A significant reduction in immature
DCX+ cells was found after 17 ds CORT (p,0.05) as well as after 21 ds CORT exposure (p,0.05) compared to the respective control groups. B3. The
number of mature DCX+ cells was significantly reduced after 17 ds CORT (p,0.005) and after 21 ds CORT exposure (p,0.001) compared to the
respective control groups. C. Both 17 ds and 21 ds CORT exposure groups showed a significant (p,0.001 and p,0.005 respectively) reduction in the
number of PCNA+ cells compared to the corresponding control groups. D. Treatment with corticosterone did not affect the number of GFAP+
astrocytes at all (p.0.05). Data are presented as mean+SEM (n= 6 animals per group). For each marker, the groups were first subjected to an ANOVA,
followed by a post-hoc Tukey multiple comparison of the means. * p,0.05; ***p,0.005; **** p,0.001.
doi:10.1371/journal.pone.0046224.g003
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cells (p,0.05 compared to 21 ds CORT+d18–21 VEHM;
Figure 4A). Surprisingly, mifepristone treatment only on d18 also
normalized the CORT-induced reduction (p,0.01) and no
significant difference was found between these two treatment
groups (21ds CORT+ds18–21 MIF versus 21ds CORT+d18 MIF;
p.0.1). Mifepristone treatment was entirely ineffective in the
vehicle (VEHC) control groups.
A highly similar pattern was observed with respect to the
number of DCX+ cells: We observed a significant overall
difference between the groups in the number of DCX+ cells
(F(5,30) = 4.2, p,0.01). Mifepristone treatment either during ds
18–21 (p,0.05) or only on d18 (p,0.05) normalized the CORT-
induced reduction in DCX+ cells (Figure 4B1). These two
treatment groups (21ds CORT+ds18–21 MIF versus 21ds
CORT+d18 MIF) yielded comparable numbers of DCX+ cells.
Follow-up analysis of various developmental stages in DCX+ cells
showed that mifepristone treatment was effective in normalizing
the CORT-induced reduction of immature DCX+ neurons to
control levels (ANOVA: F(5,30) = 4.4, p,0.005; Figure 4B2). Both
the 21ds CORT+d18 MIF and 21 ds CORT+ds18–21 MIF
groups differed significantly (p,0.05) from the 21ds
CORT+ds18–21 VEHM group. The number of mature DCX+
cells was also different among the treatment groups (F(5,30) = 5.2,
p,0.005; Figure 4B3). However, post-hoc analysis of the groups
showed that mifepristone was ineffective in restoring the CORT-
induced reduction in the number of mature DCX+ cells. CORT-
treated animals receiving mifepristone for 4 days (21ds
CORT+ds18–21 MIF) still had a significantly lower number of
mature DCX+ cells than the corresponding vehicle group (p,0.05
vs 21ds VEHC+ds18–21 MIF). This group did not differ
significantly (p.0.05) from the CORT-treated group receiving
MIF only on d18.
A similar overall pattern was observed for the proliferation
marker PCNA (ANOVA: F(5,30) = 6.6, p,0.001; Figure 4C).
Thus, mifepristone administration on d18 alone (p,0.05) or
during ds18–21 (p,0.01) normalized CORT- induced reduction
in PCNA+ cells; in this respect the two mifepristone-treated groups
were indistinguishable. Again, mifepristone treatment had no
effect in the VEHC groups. We did not observe a significant
overall effect of treatment on GFAP staining (ANOVA:
F(5,19) = 2.649, p.0.05; Figure 4D).
Double immunofluorescent staining for DCX and the prolifer-
ation marker Ki-67 revealed several co-labeled cells in the 21ds
CORT+d18 MIF group indicating that a subset of the neurogenic
cells is actively engaged in proliferation after MIF treatment (see
example in Fig. 2H). This was not observed in the vehicle-treated
control group (not shown).
In conclusion, for all proliferation and survival markers,
mifepristone treatment on d18 alone was as effective as treatment
on ds18–21.
Discussion
This study set out to elaborate on our previous findings that a
GR-antagonist can rapidly reverse the reductions in adult
neurogenesis caused by chronic stress exposure [35] or prolonged
corticosterone administration [36]. In the current study, we
replicated this phenomenon and provide evidence that GR-
antagonist mifepristone does not achieve its effect by rescuing
vulnerable cells from a late cell death, but rather by reversing the
ongoing corticosterone-induced attenuation of cell proliferation,
and thereby stimulating extra rounds of cell division. Surprisingly,
also a single day treatment on day 18 had exactly the same effect
as when the drug was given for 4 consecutive days.
Experimental design
We chose to treat rats with corticosterone for 21 days, rather
than exposing them to daily stress. While daily corticosterone
treatment is essentially different from chronic stress, the common
element in both paradigms is the extended over-exposure to
corticosterone. Since both approaches cause strongly overlapping
effects on neurogenic process [35,36], corticosterone seems to be
an important mediator. We therefore selected the more straight-
forward (and easier to accomplish) protocol of corticosterone
administration for 21 days. Extrapolation of these findings to
conditions of chronic stress, however, should be done with care.
The phenotype of 21ds corticosterone administration is robust.
Earlier experiments had shown that this regime strongly reduces
body weight gain as well as adrenal and thymus weight [36,50].
We here only examined body weight gain and observed a severe
attenuation in body weight gain in all corticosterone treatment
groups, i.e. also after 17ds of hormone administration. We did
observe some effects of mifepristone on body weight, but these
were only small and not entirely consistent. For instance, in
corticosterone-treated animals mifepristone administration on d18
caused a less severe attenuation in body weight gain compared to
animals receiving no mifepristone, but this was not seen with
mifepristone treatment for 4 consecutive days.
Mifepristone has a strong affinity for the GR, preventing
transactivation of GR-responsive genes [51]. However, this
compound also binds to progesterone receptors. Although the
anti-progesterone activity is likely limited in adult male rats, we
cannot entirely exclude some of the observed affects were due to
mixed pharmacological profile of mifepristone. We nevertheless
decided to use this drug, to allow easy comparison with earlier
studies in rats and men [11,12,13,14,35,36,51,52,53,54,55,56,57].
A potential limitation of the present study is that an extra
experimental group treated with vehicle only on d18 was not
included. This was done as a 21ds CORT+ds18 VEHM group
was expected not to be different from the 21ds CORT+ds18–21
VEHM animals, which we did examine. Although one could
reason that 4 days of (oral) VEHM administration is more stressful
than just 1 day, it should be noted that all animals already received
an injection (CORT or VEHC) in the morning, so that the added
stress of VEHM delivery was probably limited. Moreover, in the
evening (during the 2nd MIF administration) CORT levels are at
the peak of circadian rhythm, so that even in the VEHC group the
relative increase in corticosterone level due to VEHM delivery was
probably low. Therefore, we expect administration of VEHM by
itself (be it once or on 4 consecutive days) will not have influenced
our data much. This is in line with the fact that both a single- and
4 consecutive-days administrations of mifepristone in the VEHC
groups did not affect any of the parameters investigated; if the
administration of mifepristone (or its vehicle) was highly stressful,
we would expect that a single versus repetitive exposure causes a
different phenotype, which was not the case. Altogether we have
no reason to assume that lack of the VEHC/CORT+d18 VEHM
groups would seriously hamper our conclusions.
Primary target of corticosterone in the neurogenic
pathway
Earlier studies have supplied evidence that chronic corticoste-
roids over-exposure affects multiple steps in the neurogenic
pathway: corticosteroids reduce proliferation [29], decrease
neuronal differentiation [31], and impair survival of adult-born
cells [32,36].
Our first experiment gives additional insight in this issue. The
results with PCNA -a marker for cell proliferation at the time of
sacrifice [58,59]- indicate corticosterone exposure reduces prolif-
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Figure 4. Effects of mifepristone given at d18 only or during ds18–21 of 3-weeks corticosterone treatment period. A. Mifepristone
treatment during ds 18–21 fully normalizes the CORT-induced reduction in number of BrdU+ cells (p,0.05 compared to 21 ds CORT+d18–21 VEHM).
Surprisingly, mifepristone treatment only on d18 also normalized the CORT-induced reduction (p,0.01). No significant difference was found between
these two treatment groups (21ds CORT+ds18–21 MIF versus 21ds CORT+d18 MIF; p.0.05). Mifepristone treatment was entirely ineffective in the
vehicle (VEHC) control groups. B1. Mifepristone treatment either during ds 18–21 (p,0.05) or only on d18 (p,0.05) normalized the CORT-induced
reduction in DCX+ cells. These two treatment groups (21ds CORT+ds18–21 MIF versus 21ds CORT+d18 MIF) yielded comparable numbers of DCX+
cells. B2. Mifepristone treatment either during ds 18–21 (p,0.05) or only on d18 (p,0.05) was effective in normalizing the CORT-induced reduction
in immature DCX+ cells. B3. Mifepristone was ineffective in restoring the CORT-induced reduction in the number of mature DCX+ cells (p.0.05 in
both treatment groups). CORT-treated animals receiving mifepristone for 4 days (21ds CORT+ds18–21 MIF) still had a significantly lower number of
mature DCX+ cells than the corresponding vehicle group (p,0.05 vs 21ds VEHC+ds18–21 MIF). C. Mifepristone administration either on d18 alone
(p,0.05) or during ds18–21 (p,0.01) normalized CORT-induced reduction in PCNA+ cells. Again, mifepristone treatment had no effect in the VEHC
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eration, both after 17 ds and 21 ds treatment. The degree of
reduction was comparable at both timepoints, suggesting an
ongoing attenuation during the daily corticosterone exposure.
Immunostaining for DCX reflects the sum of neuronal differen-
tiation and survival of migratory young neurons born 4–14 days
before staining [40]. Given the attenuated proliferation indicated
by PCNA staining on d18, the reduction in number of immature
DCX+ cells seen on d22 (partly reflecting cells that were born
around d18) could be well explained by a reduced proliferation of
cells that subsequently differentiate into neurons. In view of the
highly comparable reduction in the number of immature DCX+
cells at d18 (which were most likely born ,d14), corticosterone
treatment may indeed suppress proliferation for most of the 21ds
treatment period. This is underlined by the extensive reduction in
number of mature DCX+ cells (a cumulative measure of cells born
during the first two weeks of treatment and differentiating into
neurons), both after 17 and 21 ds corticosterone exposure.
Nevertheless, additional corticosterone effects on neuronal differ-
entiation and/or survival cannot be excluded. A shift from
neuronal into glia phenotype seems unlikely, because the number
of GFAP+ cells is not altered; however, it is possible that changes in
differentiation may remain unnoticed, since the number of
newborn cells becoming GFAP+ is only a fraction of the total
pool of GFAP+ cells [60,61,62].
In our experimental design, BrdU staining reflected the survival
of cells that were derived-probably after several rounds of
replication- from a subgroup of cells born on day 1. If we assume
an ongoing suppression of replication by corticosterone, the
reduced number of BrdU+ cells both at d18 and d22 can be
understood in the absence of any steroid effect on cell survival or
even with increased cell survival. However, if cells incorporating
BrdU on d1 did not undergo several rounds of replication, the
findings support the view that corticosterone impairs survival of
newborn cells.
Collectively, although additional hormonal influences on
differentiation and survival of newborn cells cannot be excluded,
the results support the view that corticosterone attenuates cell
proliferation and adult neurogenesis, probably for most of period
in which the hormone is administered.
Effects of mifepristone
The findings with PCNA indicate that mifepristone normalized
corticosterone-induced attenuation in cell proliferation. As the
antagonist was ineffective in VEHC-treated animals, we conclude
that mifepristone -rather than e.g. through additional pathways-
prevents corticosterone from exerting suppressive effect on
proliferation. Surprisingly, this was not only seen when mifepris-
tone was administered during the days preceding the moment on
which proliferative activity was probed (d22), but even when it was
given just on d18, i.e. 4 days before PCNA staining. Thus, despite
continued presence of corticosterone after d18 and the presumed
absence of mifepristone at that time- its presence at d19–21 can be
ruled out in view of the short half-life time [63,64]- later
corticosterone no longer seems able to reduce proliferation or
overrule the proliferative changes initiated at d18.
The observations with DCX are also compatible with the view
that mifepristone prevents corticosterone not only from reducing
proliferation, but also from reducing the number of cells that
lateron develop into neuronal phenotype. The number of
immature DCX+ cells (which were born on d18 or earlier) was
fully restored by mifepristone. The fact that corticosterone-
induced reduction in the number of mature DCX+ cells was not
normalized fits with this view, since the proliferation giving rise to
these cells probably took place before mifepristone was adminis-
tered. Incidentally, if mifepristone would primarily prevent a
putative corticosterone-induced suppression in cell survival, one
would expect that the number of mature DCX+ cells is also (partly)
normalized by mifepristone; since the number of mature DCX+
cells in the 21ds CORT+ds18–21 MIF group was significantly
lower than that in the 21ds VEHC+ds18–21 MIF group, this
strongly argues against effects of corticosterone and mifepristone
on cell survival per se. Similar to the PCNA results, mifepristone
on d18 alone was as effective as a 4ds delivery in normalizing the
number of immature DCX+ cells. This is less surprising, since
DCX immunoreactivity discerned on d22 most likely reflects
neurons born at d18 or earlier.
A significant proportion of the newborn cells in adult SGZ
undergoes apoptosis, most likely within their first week of life
[39,65]. Earlier studies have suggested that GR activation may
play a pivotal role in glucocorticoid-induced apoptosis and
proliferation [66,67], whereas mifepristone pre-treatment could
e.g. prevent stress-induced apoptosis of hippocampal newborn
neurons [56]. Albeit in osteoblastic cells, mifepristone also
abolishes the GR agonist dexamethasone (DEX)-induced apopto-
sis and G0/G1 arrest and increases cell proliferation, an effect that
may be mediated through GR [68]. At the start, we considered the
possibility that mifepristone may exclusively act by preventing
death of a group of neurons [56] at d18 or later. If so, we would
expect the number of BrdU+ cells to be comparable up to d18 and
then drop dramatically. However, this was not the case
(experiment #1). Since the equilibrium between proliferation
and death of cells born on d1 (reflected by the number of BrdU+
cells) can be fully restored by mifepristone, and in view of the
findings with PCNA and DCX, we conclude that normalization in
the number of BrdU+ cells at d22 by mifepristone is caused by the
drug preventing attenuation of proliferation caused by corticoste-
rone. In fact, mifepristone may, either directly or indirectly, also
stimulate proliferation of some neurogenic cells. As shown in
Fig. 2H, a small subset of the DCX+ cells were co-labeled for the
proliferation marker Ki-67 indicating that at least some of the
neurogenic cells can re-engage in proliferation. Earlier, Walker et
al. [69], using fluorescence-activated cell sorting (FACS), could
demonstrate that of the DCX+ cells those with relatively low levels
of DCX per cell were capable of dividing again.
As was argued above for PCNA, the BrdU data support the
concept that a single mifepristone administration is sufficient to
prevent subsequent corticosteroid-effects at least for several days,
even in the continued presence of corticosterone. Regarding this
rapid normalization, several similar observations exist in literature
in which e.g. the HPA axis or opioid system were ‘reset’ already
after a short stimulus; for example, a short inescapable stressor
produced long-lasting changes in the brain-pituitary-adrenal axis
of adult male rats, while a single administration of interleukin-1
causes long-lasting changes in HPA sensitization [70,71,72].
Moreover, also for opioid sensitivity, similar ‘swicth-like’ effects
have been described [73,74,75].
In conclusion, the current study provides evidence that
repetitive corticosterone administration primarily attenuates pro-
groups. D. No significant overall effect of treatment was found on GFAP+ cells number (p.0.05). Data are presented as mean 6 SEM (n= 6 animals
per group). For each marker, the groups were first subjected to an ANOVA, followed by a post-hoc Tukey multiple comparison of the means. *
p,0.05; ** p,0.01; ***p,0.005; **** p,0.001.
doi:10.1371/journal.pone.0046224.g004
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liferation and more specifically neurogenesis, in the rat DG. This is
prevented already by a brief administration of a GR-antagonist.
Surprisingly, also a single day administration of the antagonist is
already sufficient to normalize the neurogenic process, possibly by
resetting their initial level of proliferation. A similar quick switch
may explain the rather rapid beneficial effects of mifepristone
observed in a small sample of patients with psychotic depression
[12,14,54,55]. This underlines that studies into therapeutical
efficacy of experimental antidepressants that target HPA-activity
should explore possibility of reducing treatment duration since this
might result in equally beneficial effects.
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